HPV-related oropharyngeal cancer now affects more US men than cervical cancer affects US women. Vaccination prevents it. Here's the practical picture.

HPV Throat Cancer — Oropharyngeal Cancer in Men

HPV-related oropharyngeal cancer (throat cancer) is one of the most dramatic shifts in cancer epidemiology of the past 20 years. Rates in US men have quintupled since the 1980s. It now affects more US men than cervical cancer affects US women.

The biggest driver: HPV-16 acquired from oral sex. The good news: it's preventable with the HPV vaccine.

Here's what to actually know.

The short answer

What it is: Cancer of the back of the throat (tonsils, base of tongue) — most caused by HPV-16
Who's at risk: Mostly men (4:1 vs women), median age 50-60
Cause: HPV acquired through oral sex
Symptoms: Persistent throat lump, sore throat, ear pain, difficulty swallowing, lump in neck
No routine screening yet — diagnosis often delayed
Vaccine prevents it — Gardasil 9 covers HPV-16
Treatment is effective — survival rates much higher than tobacco-related throat cancer

How HPV causes throat cancer

HPV-16 integrates into the DNA of cells at the base of the tongue and tonsils. Over decades:

Cellular changes accumulate
Some cells become precancerous
Eventually, a few become invasive cancer
Process takes 15-30 years from exposure

So the cancer epidemic we see now in 2026 reflects exposures that happened in the 1990s and 2000s — well before broad HPV vaccination.

Who gets HPV throat cancer

Risk factors

Male sex — 4x higher than women
Multiple lifetime oral sex partners
HPV-16 infection (most carry it transiently without symptoms)
Smoking — adds significantly to risk (multiplicative)
Heavy alcohol use — adds to risk
Immunosuppression — HIV+ patients especially

Demographics

Median age at diagnosis: 50-60
More common in white men than black/Hispanic men (currently)
Less correlated with smoking than older throat cancers — many patients are non-smokers

Symptoms — when to act

The challenge: early HPV throat cancer often has subtle symptoms or none.

Concerning signs (over 2 weeks duration)

Persistent sore throat
Lump in the neck (often the first noticed symptom — swollen lymph node)
Painless lump in the back of the throat or on the tonsil
Difficulty swallowing
Ear pain (referred pain from throat)
Hoarseness
Unilateral tonsil enlargement (one tonsil bigger than the other)
Coughing up blood
Unexplained weight loss

Don't ignore

"I just have a sore throat from a cold" that lasts 3+ weeks
"It's probably tonsillitis" with one-sided swelling

See your doctor if symptoms persist > 2-3 weeks.

How HPV throat cancer is diagnosed

Initial evaluation

ENT (otolaryngology) exam
Visual inspection of throat, including fiber-optic exam
Biopsy of any suspicious lesion or enlarged node
Imaging (CT, MRI, PET-CT) for staging

HPV testing of tissue

Biopsy specimen is tested for HPV-16
"p16-positive" usually indicates HPV-related cancer
HPV-positive vs HPV-negative cancers have different outlooks

Why there's no routine screening (yet)

Unlike cervical cancer (Pap smear), HPV throat cancer doesn't have a validated screening tool for the general population. Reasons:

Anatomical location is harder to visualize routinely
Most HPV in the throat clears spontaneously
No good biomarker (yet) for detecting precancer
Cost-effectiveness unclear at population level

What is being studied

Oral HPV testing (saliva sample) — research stage
Plasma circulating tumor DNA (HPV ctDNA) — being studied for high-risk groups
Annual examination by dentist looking for unusual lesions
Some advocacy for screening in MSM, HIV+ men, high-risk populations

What you can do

Annual physical examination including throat inspection
Notice unilateral throat changes
Don't dismiss persistent sore throats

Treatment

Standard approach

Surgery + radiation — most common
Chemotherapy + radiation (chemoradiation) — for some patients
Transoral robotic surgery (TORS) — minimally invasive option
Immunotherapy — increasing role for advanced disease

Survival rates

HPV-positive throat cancer has much better survival than tobacco-related throat cancer
5-year survival for HPV+ oropharyngeal cancer: ~85% (early-stage), ~70-80% overall
HPV-negative tobacco-related: ~40-50% overall

Side effects of treatment

Dry mouth (radiation)
Difficulty swallowing
Speech changes
Neck disfigurement (surgery)
Long-term issues including jaw bone problems

Treatment for throat cancer is intense — but outcomes for HPV+ disease are significantly better than they used to be.

The HPV vaccine and throat cancer prevention

Gardasil 9

Covers HPV-16 (the main throat cancer driver) + 8 other strains
Prevents future HPV infection from these strains
Most effective if given before sexual debut
Approved through age 26 routinely; can be given through age 45
2-dose schedule for under-15 starters; 3-dose for older

Evidence for HPV throat cancer prevention

Vaccination reduces oral HPV infection in young adults
Long-term data (20+ years) for throat cancer prevention is still being collected
Modeling suggests vaccinated cohorts will have substantially lower rates
It's been a particular focus for boys' vaccination since 2011

If you're already an adult

Vaccination still recommended through 26
Discuss with provider if 27-45 — coverage varies
Even if you've been exposed to some HPV strains, vaccine protects against others

See HPV vaccine for adults over 26.

Smoking and alcohol matters

HPV+ throat cancer risk is higher in smokers than non-smokers. Smoking + HPV is significantly worse than either alone.

Quitting smoking reduces risk
Heavy alcohol use compounds risk
The "good outcomes" for HPV+ throat cancer apply mainly to non-smokers

What to talk to your dentist about

Dentists can spot:

Unusual lesions in the throat
Asymmetric tonsils
Persistent oral or pharyngeal abnormalities

Some dentists are trained in HPV oral cancer screening as part of routine cleanings. Ask if yours does this.

When to see an ENT

Throat symptoms persistent > 3 weeks
Lump in the neck
Unilateral tonsil enlargement
Hoarseness > 3 weeks
Difficulty swallowing
After a primary care evaluation when concern remains

Same-day visits aren't always available. If urgent, request it.

Special situations

HIV+ patients

Higher risk of HPV-related cancers
More aggressive surveillance recommended
Discuss with HIV provider

Sexual orientation

Men who have sex with men (MSM) have higher oral HPV prevalence
Screening recommendations are evolving

Previous cancer or pre-cancer

Increased surveillance
Vaccination still beneficial

Common questions

"Can I get HPV throat cancer from oral sex once?" Theoretically yes, but odds of a single exposure leading to cancer are very low. Most HPV in the throat clears.

"My partner has HPV — am I at risk?" Possibly, but most exposures don't lead to cancer. Vaccination if eligible. Watch for symptoms.

"Should I get tested for oral HPV now?" Not routinely. Tests exist but aren't widely used clinically yet.

"Can a Pap-like test be done for throats?" Research is ongoing. Not yet validated for clinical use.

"How long does it take from HPV exposure to throat cancer?" Average 15-30 years.

"I already had a 'sore throat' for years — am I at high risk?" Not necessarily — most throat soreness has benign causes. But if it's persistent and unexplained, see a doctor.

Bottom line

HPV throat cancer (oropharyngeal cancer) is:

Caused mainly by HPV-16 acquired through oral sex
More common in men by 4:1
Preventable with vaccination — Gardasil 9
Treatable with much better outcomes than tobacco-related throat cancer
Not yet routinely screened — diagnosis often delayed
Worth watching for symptoms in your 40s-50s

If you're under 26: Get vaccinated if not already. If you're 27-45: Discuss HPV vaccination with your doctor. Any age: Pay attention to persistent throat or neck symptoms. Smokers: Quit.

The current generation of vaccinated young people will benefit enormously. For older adults, awareness + symptom recognition + lifestyle are the main protections.

For more on HPV, see our HPV pillar guide, HPV vaccine for adults over 26, HPV in men, and anal cancer screening for MSM.